Skip to main content

LakeShore Biopharma Co., Ltd.

corporate_fare Company Profile

LakeShore Biopharma Co., Ltd.

LSBCF·OTC·Life Sciences·CIK 0001946399

LakeShore Biopharma Co., Ltd. is a biopharmaceutical company that discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics. The company focuses on infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine that is currently marketed. Other products in development include PIKA, a rabies vaccine in Phase I/III and preclinical trials for rabies virus, and PIKA YS-ON-001, an immuno-oncology therapeutic candidate in Phase I trials for pancreatic and hepatocellular cancer. The pipeline also features PIKA YS-HBV-001, a hepatitis B vaccine in Phase I trials, and PIKA YS-HBV-002, an immune-therapy vaccine in preclinical trials for chronic HBV infection. Additionally, PIKA YS-ON-001 and PIKA Influenza Vaccine are in preclinical trials. The company was founded in 1994 as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd. in May 2024. LakeShore Biopharma Co., Ltd. is based in Beijing, China.

LakeShore Biopharma Co., Ltd. (OTC:LSBCF) is a publicly traded company in the Life Sciences sector. Wiseek monitors LSBCF SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • LakeShore Biopharma Sets Shareholder Meeting to Vote on Going-Private Merger
  • Definitive Proxy Filed for Going-Private Merger at $0.066/Share; Shareholder Vote Set for June 19
  • LakeShore Biopharma Finalizes Going-Private Terms at Drastically Reduced Price of $0.066 Per Share Amid Massive Liabilities
  • Going-Private Merger Consideration Drastically Cut by 92.7% to $0.066 Per Share
  • LakeShore Biopharma Amends Go-Private Deal, Cuts Shareholder Payout by 92%

Financial Snapshot

Fiscal year ended March 31, 2025
Revenue
¥614.96M CNY
Net Income
-¥99.98M CNY
Diluted EPS
-¥5.22 CNY
Op. Cash Flow
-¥120.98M CNY
Free Cash Flow
-¥133.69M CNY
Gross Profit
¥507.19M CNY
Operating Income
-¥86.29M CNY
Cash & Equivalents
¥28.08M CNY
Total Debt
¥413.94M CNY
Debt / Equity
0.83×
Net Margin
-16.3%
Shares Outstanding
20.77M sh
Source: 20-F · filed 2025-07-31 · accession 0001213900-25-069880

Insider Transactions

LSBCF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with L →
$0.07
52-week range · as of 2026-05-28 $0.0278 – $2.8
Market cap
$2.88M
Volume
1K (0.1× avg)
3-mo avg 10.5K
Live data · 2026-06-14 06:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LSBCF - Latest Insights

LSBCF
May 28, 2026, 9:25 AM EDT
Filing Type: 6-K
Importance Score:
7
LakeShore Biopharma Sets Shareholder Meeting to Vote on Going-Private Merger
Price at Filing: $0.0993
Real-time Price: $0.070 info
Change: -$0.0293 (-30%) info
Market Cap: $2.885M info
Sentiment: Negative
View Wiseek Article
LSBCF
May 28, 2026, 8:41 AM EDT
Filing Type: SC 13E3/A
Importance Score:
9
Definitive Proxy Filed for Going-Private Merger at $0.066/Share; Shareholder Vote Set for June 19
Price at Filing: $0.0993
Real-time Price: $0.070 info
Change: -$0.0293 (-30%) info
Market Cap: $2.885M info
Sentiment: Negative
View Wiseek Article
LSBCF
May 08, 2026, 9:10 AM EDT
Filing Type: SC 13E3/A
Importance Score:
9
LakeShore Biopharma Finalizes Going-Private Terms at Drastically Reduced Price of $0.066 Per Share Amid Massive Liabilities
Price at Filing: $0.037
Real-time Price: $0.070 info
Change: +$0.033 (+89%) info
Market Cap: $2.885M info
Sentiment: Negative
View Wiseek Article
LSBCF
Apr 29, 2026, 9:08 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
10
Going-Private Merger Consideration Drastically Cut by 92.7% to $0.066 Per Share
Price at Filing: $0.0278
Real-time Price: $0.070 info
Change: +$0.0422 (+152%) info
Market Cap: $2.885M info
Sentiment: Negative
View Wiseek Article
LSBCF
Apr 29, 2026, 8:12 AM EDT
Filing Type: 6-K
Importance Score:
9
LakeShore Biopharma Amends Go-Private Deal, Cuts Shareholder Payout by 92%
Price at Filing: $0.0278
Real-time Price: $0.070 info
Change: +$0.0422 (+152%) info
Market Cap: $2.885M info
Sentiment: Negative
View Wiseek Article
LSBCF
Apr 29, 2026, 8:03 AM EDT
Source: EQS
Importance Score:
9
LakeShore Biopharma Slashes Going-Private Offer Price to $0.066 Per Share, Down From $0.90
Price at Filing: $0.0278
Real-time Price: $0.070 info
Change: +$0.0422 (+152%) info
Market Cap: $2.885M info
Sentiment: Negative
View Wiseek Article
LSBCF
Mar 25, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
LakeShore Biopharma Receives Revised Non-Binding Acquisition Proposal
Price at Filing: $0.045
Real-time Price: $0.070 info
Change: +$0.025 (+56%) info
Market Cap: $2.885M info
Sentiment: Positive
View Wiseek Article